GlassScriptPhysician profile
Sally E Mcdonald
NPI 1053853804
$3,978.41
in general payments reported to CMS, 2019-2025
44 companies · $764 in 2025
The $764 reported for 2025 was more than what 80% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $48.14 · 2022: $386 · 2023: $1,511 · 2024: $1,270 · 2025: $764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,376 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,375.66 |
| Education | $168.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $432.56 | 2023-2025 | Piqray, Kisqali |
| Merck Sharp & Dohme LLC | $375.65 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Gilead Sciences, INC. | $211.72 | 2023-2024 | |
| Sobi, INC | $210.29 | 2023-2025 | |
| Astellas Pharma US INC | $207.61 | 2023-2024 | Xospata, Padcev |
| Bayer Healthcare Pharmaceuticals INC. | $185.43 | 2022-2024 | |
| Incyte Corporation | $179.67 | 2022-2025 | Monjuvi, Jakafi, Zynyz |
| Janssen Biotech, INC. | $148.55 | 2022-2024 | Erleada, Akeega, Rybrevant |
| Eisai INC. | $145.87 | 2022-2025 | |
| Emd Serono, INC. | $136.76 | 2023-2025 | Bavencio |
| Daiichi Sankyo INC. | $132.70 | 2023-2025 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $127.66 | 2022-2025 | Opdivo |
| Abbvie INC. | $121.80 | 2024-2025 | |
| Lilly USA, LLC | $112.72 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Regeneron Healthcare Solutions, INC. | $109.83 | 2023-2024 | Libtayo |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $106.33 | 2023-2024 | Krazati |
| Glaxosmithkline, LLC. | $85.43 | 2023-2025 | Zejula, Jemperli, Ojjaara |
| Astrazeneca Pharmaceuticals LP | $81.59 | 2023-2025 | Imfinzi, Calquence, Lynparza |
| Genentech USA, INC. | $70.27 | 2023-2025 | Venclexta, Perjeta, Kadcyla |
| Pfizer INC. | $69.52 | 2023-2024 | |
| Seagen INC. | $62.34 | 2023 | Tukysa, Adcetris, Padcev |
| Tersera Therapeutics LLC | $59.16 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $57.53 | 2023-2024 | |
| Pharmaessentia USA Corporation | $52.29 | 2023-2025 | Besremi |
| Servier Pharmaceuticals LLC | $43.60 | 2023-2025 | |
| Stemline Therapeutics INC. | $41.54 | 2023-2025 | Orserdu |
| Aveo Pharmaceuticals, INC. | $36.86 | 2021-2023 | Fotivda |
| Adc Therapeutics America, INC. | $35.62 | 2024 | |
| Alexion Pharmaceuticals, INC. | $35.10 | 2023-2024 | Ultomiris |
| Agios Pharmaceuticals, INC. | $32.10 | 2023 | Pyrukynd |
| Takeda Pharmaceuticals U.S.A., INC. | $26.96 | 2025 | Vpriv |
| Genzyme Corporation | $25.17 | 2022 | |
| Foundation Medicine, INC. | $23.93 | 2023 | |
| Myriad Genetic Laboratories, INC. | $22.23 | 2023 | Precisetumor |
| Celgene Corporation | $21.18 | 2025 | Reblozyl |
| Taiho Oncology, INC. | $20.07 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $18.40 | 2022 | |
| Corcept Therapeutics | $17.82 | 2025 | Korlym |
| Alnylam Pharmaceuticals INC. | $16.78 | 2022 | |
| Teleflex LLC | $16.67 | 2025 | Arrow |
| Karyopharm Therapeutics INC. | $16.20 | 2022 | |
| Puma Biotechnology, INC. | $15.64 | 2023 | |
| Exelixis INC. | $14.80 | 2023 | Cabometyx |
| Acrotech Biopharma INC. | $14.46 | 2024 | Beleodaq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sally Mcdonald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.